BRIEF-Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)

* Co and Pfizer Inc announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS)

Positive 0 LOL 0 Interesting 0 Sad 0 Revolting 0 Fake 0

See also

One dead, dozens injured in cosmetics factory explosions

A man is killed and dozens of other workers and firefighters are injured in two explosions and a fire at a New York cosmetics factory, which has been cited for nine occupational safety violations this year.

0 0

Whoops, looks like something went wrong.